<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">
<link rel=File-List href="./Page3_files/filelist.xml">
<link rel=Edit-Time-Data href="./Page3_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title> </title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>jennifer</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>jennifer</o:LastAuthor>
  <o:Revision>14</o:Revision>
  <o:TotalTime>167</o:TotalTime>
  <o:Created>2006-10-11T14:46:00Z</o:Created>
  <o:LastSaved>2006-10-12T13:30:00Z</o:LastSaved>
  <o:Pages>2</o:Pages>
  <o:Words>737</o:Words>
  <o:Characters>4206</o:Characters>
  <o:Company>EMBL-EBI</o:Company>
  <o:Lines>35</o:Lines>
  <o:Paragraphs>8</o:Paragraphs>
  <o:CharactersWithSpaces>5165</o:CharactersWithSpaces>
  <o:Version>9.6926</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>75</w:Zoom>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1 -369098753 63 0 4129023 0;}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1 -369098753 63 0 4129023 0;}
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:16.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Arial Unicode MS";
	mso-font-kerning:16.0pt;}
h2
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:14.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Arial Unicode MS";
	font-style:italic;}
h3
	{mso-style-next:Normal;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:12.0pt;
	font-family:"Times New Roman";
	color:navy;
	font-weight:normal;
	font-style:italic;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:36.0pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:72.0pt 90.0pt 72.0pt 90.0pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
 /* List Definitions */
@list l0
	{mso-list-id:138304141;
	mso-list-type:hybrid;
	mso-list-template-ids:370963604 1696212148 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:82.35pt;
	mso-level-number-position:left;
	margin-left:82.2pt;
	text-indent:-17.85pt;
	mso-ansi-font-size:8.0pt;
	font-family:Symbol;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1029"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-GB link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<p class=MsoNormal><a href="http://www.ebi.ac.uk/interpro/"
title="To the InterPro database"><span style='text-decoration:none;text-underline:
none'><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:139.5pt;
 height:45pt'>
 <v:imagedata src="./Page3_files/image001.png" o:title="InterPro"/>
</v:shape><![endif]--><![if !vml]><img border=0 width=186 height=60
src="./Page3_files/image002.jpg" v:shapes="_x0000_i1025"><![endif]></span></a></p>

<h1 align=center style='text-align:center'><span style='font-size:28.0pt;
mso-bidi-font-size:16.0pt;color:navy'>Cytochrome&nbsp;P450<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span style='font-size:14.0pt;mso-bidi-font-size:16.0pt;color:navy'>Cytochrome
P450 and the Drug Response<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>Most drugs are
cleared by CYP proteins.<span style="mso-spacerun: yes">  </span>Drugs can
increase or decrease the activity of one or more CYP enzymes, which alters the
rate at which the drug is degraded and cleared from the body.<span
style="mso-spacerun: yes">  </span>This can work both ways.<span
style="mso-spacerun: yes">  </span>When a drug increases the activity of a CYP
protein, CYP can render the drug ineffective, because it is cleared too quickly
from the body.<span style="mso-spacerun: yes">  </span>Alternatively, when a
drug inhibits a CYP protein, CYP may not prevent the drug from accumulating to
toxic levels, even to the extent of causing an overdose.<span
style="mso-spacerun: yes">  </span></p>

<p class=MsoBodyText style='text-indent:36.0pt'>Of the several families of CYP
proteins, CYP1, CYP2, CYP3 and CYP4 are the most important in terms of drug
biotranformations, especially CYP3A4, which is the most prevalent CYP in the
body and metabolises several drugs. <span style="mso-spacerun: yes"> </span>CYP
proteins can affect many aspects of a drug’s response in a patient, some of
which are listed below.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3>Drug response variability </h3>

<p class=MsoBodyText><span style='mso-tab-count:1'>            </span>Medicines
can have different responses in different people, some drugs being rendered
ineffective, others causing adverse reactions.<span style="mso-spacerun: yes"> 
</span>Drug variability is largely due to differences in CYP protein activity,
caused by polymorphic variations between people, age or environmental factors
such as diet. <span style="mso-spacerun: yes"> </span>By far the greatest
factor is genetic predisposition due to polymorphic variations, as discussed
previously.</p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>In addition, a
person’s level of various CYP proteins can vary with age.<span
style="mso-spacerun: yes">  </span>For example, newborns do not express CYP1A2,
making them susceptible to the toxic effects of caffeine.<span
style="mso-spacerun: yes">  </span>In recent years, various screens have become
available to test a person’s level of the major CYP proteins involved in drug clearance,
in order to help predict drug tolerance.</p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3 style='text-align:justify'>Drug-drug interactions </h3>

<p class=MsoBodyText style='text-indent:36.0pt'>In addition to affecting its
own rate of clearance, drugs can affect the rate of clearance of other drugs, causing
drug-drug interactions.<span style="mso-spacerun: yes">  </span>Therefore, a
drug may be cleared properly from the body, but it could affect the clearance
of a second drug taken at the same time by affecting its CYP clearance protein,
causing the second drug to accumulate to dangerous levels.<span
style="mso-spacerun: yes">  </span>For this reason, taking different
medications is strictly controlled by doctors.</p>

<p class=MsoBodyText><span style="mso-spacerun: yes">  </span></p>

<h3>Food-drug interactions </h3>

<p class=MsoBodyText><span style='mso-tab-count:1'>            </span>Even
natural substances found in foods can affect CYP proteins, which in turn can
alter drug responses.<span style="mso-spacerun: yes">  </span>For example,
grapefruit contains bioactive compounds such as bergamottin that can inhibit
CYP3A4, an important CYP enzyme required to degrade several types of drugs,
thereby increasing the risk of toxicity and adverse affects with those drugs.<span
style="mso-spacerun: yes">  </span>Drugs known to interact with grapefruit
include statins, antiarrhythmic agents, immunosuppressive agents, and calcium
channel blockers.<span style="mso-spacerun: yes">  </span>It is generally
advised that people on these types of medications avoid the consumption of
grapefruit.<span style="mso-spacerun: yes">  </span>Other bioactive foods that
affect CYP3A4 enzymes include pomegranate juice and red wine, as well as St
John’s wort extracts.</p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3>Drug bioactivation </h3>

<p class=MsoBodyText><span style='mso-tab-count:1'>            </span>Besides
being degraded and cleared, some drugs can also be activated to form potent
metabolites. <span style="mso-spacerun: yes"> </span>Bioactivation occurs
primarily in the liver, but can also occur in kidneys, skin, lung and
intestine.<span style="mso-spacerun: yes">  </span>For example, it is estimated
that about 3-4% of ingested codeine (an opium alkaloid) can be converted in the
liver to morphine, providing much of the drug’s analgesic effect.<span
style="mso-spacerun: yes">  </span></p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span style='font-size:14.0pt;mso-bidi-font-size:16.0pt;color:navy'>Drug Testing<o:p></o:p></span></h1>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyTextIndent>New drugs coming onto the market must be tested against
cytochrome P450 enzymes in several ways.</p>

<p class=MsoBodyTextIndent><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyTextIndent align=left style='margin-left:82.2pt;text-align:
left;text-indent:-17.85pt;mso-list:l0 level1 lfo1;tab-stops:list 82.35pt'><![if !supportLists]><span
style='font-size:8.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><b>Clearance rate</b> of a drug must be determined for accurate
dosage determination. <span style="mso-spacerun: yes"> </span>If a drug is extensively
metabolised after oral administration by liver enzymes, rendering it inactive before
it can be circulated (high first-pass effect), then it may be tested for
administration by other routes, such as by injection.</p>

<p class=MsoBodyTextIndent><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyTextIndent align=left style='margin-left:82.2pt;text-align:
left;text-indent:-17.85pt;mso-list:l0 level1 lfo1;tab-stops:list 82.35pt'><![if !supportLists]><span
style='font-size:8.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><b>Bioactivation</b> of a drug must be determined to
avoid undesired side effects that are only seen after transformation by the
liver.<span style="mso-spacerun: yes">  </span>Frequently, drugs that seem desirable
during development will be rendered toxic after a liver enzyme assay. <span
style="mso-spacerun: yes"> </span>However, sometimes bioactivation may be important
for the efficacy of a drug, such as with the conversion of codeine to
morphine.<span style="mso-spacerun: yes">  </span></p>

<p class=MsoBodyTextIndent><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyTextIndent align=left style='margin-left:82.2pt;text-align:
left;text-indent:-17.85pt;mso-list:l0 level1 lfo1;tab-stops:list 82.35pt'><![if !supportLists]><span
style='font-size:8.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><b>Activation/inhibition of CYP proteins</b> by a drug
need to be determined in order to predict drug-drug interactions.<span
style="mso-spacerun: yes">  </span>Drugs are tested to see whether they affect
the activity of any CYP proteins.<span style="mso-spacerun: yes">  </span>If
they do, they must not be given in conjunction with drugs known to be cleared
by those CYP proteins. </p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyText><span style='mso-tab-count:1'>            </span>Detailed
information exists regarding the metabolism and clearance of drugs by specific
CYP proteins, which is useful for predicting potential drug interactions.<span
style="mso-spacerun: yes">  </span>Some useful websites are:</p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyText align=left style='text-align:left'><i>Table and data of
human CYP proteins</i>: <a href="http://drnelson.utmem.edu/hum.html">http://drnelson.utmem.edu/hum.html</a></p>

<p class=MsoBodyText align=left style='text-align:left'><i>Drug interactions</i>:
<a href="http://medicine.iupui.edu/flockhart/">http://medicine.iupui.edu/flockhart/</a></p>

<p class=MsoBodyText align=left style='text-align:left'><i>Table of CYP protein
alleles</i>: <a href="http://www.cypalleles.ki.se/cyp2c19.htm">http://www.cypalleles.ki.se/cyp2c19.htm</a></p>

<p class=MsoBodyText align=left style='text-align:left'><i>Tables of metabolism,
induction and inhibition of various drugs, CYP proteins and foods</i>: <a
href="http://www.edhayes.com/startp450.html">http://www.edhayes.com/startp450.html</a></p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h2 align=center style='text-align:center'><span style='font-size:16.0pt;
mso-bidi-font-size:14.0pt;font-style:normal'>Next:<span style="mso-spacerun:
yes">  </span><a href="Page4.htm" title="Page 4">Cytochrome P450 and Cancer</a><o:p></o:p></span></h2>

<h2 align=center style='text-align:center'><span style='font-size:16.0pt;
mso-bidi-font-size:14.0pt;font-style:normal'>Previous:<span
style="mso-spacerun: yes">  </span><a href="Page2.htm" title="Page 2">A Wealth
of Enzymes</a></span><span style='font-style:normal'><o:p></o:p></span></h2>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

</div>

</body>

</html>
